Evidence map›Paper›PMID 38798314›Full record

ArticlebioRxiv : the preprint server for biology2024

Lisa R Goldberg, Britahny M Baskin, Yahia Adla, Jacob A Beierle, Julia C Kelliher, Emily J Yao, Stacey L Kirkpatrick, Eric R Reed, David F Jenkins, Jiayi Cox and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Lisa R GoldbergLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Britahny M BaskinLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Yahia AdlaLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Jacob A BeierleLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Julia C KelliherLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Emily J YaoLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Stacey L KirkpatrickLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Eric R ReedGraduate Program in Bioinformatics, Boston University, Boston, MA USA.
David F JenkinsGraduate Program in Bioinformatics, Boston University, Boston, MA USA.
Jiayi CoxGenetics and Graduate Program in Genetics and Genomics, Program in Biomedical Sciences, Boston University Chobanian & Avedisian School of Medicine.
Alexander M LuongLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Kimberly P LuttikLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Julia A ScotellaroLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Timothy A DrescherLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Sydney B CrottsLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Neema YazdaniLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Martin T FerrisDepartment of Genetics, University of North Carolina, Chapel Hill, NC USA.
W Evan JohnsonDivision of Infectious Disease, Department of Medicine, Center for Data Science, Rutgers University, New Jersey, USA.
Megan K MulliganDepartment of Genetics, Genomics, and Informatics, University of Tennessee Health Science Center, Memphis, TN USA.
Camron D BryantLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.

Funding

A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypesU01DA050243 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D, ZACHARIOU, VENETIA · 2020 to 2023
$3.3M
Systems genetics of premorbid and cocaine use traits in a rat reduced complexity crossU01DA055299 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D, KANTAK, KATHLEEN M. · 2022 to 2025
$2.8M
Training Program on Development of Medications for Substance Use DisorderT32DA055553 · NIDA · NORTHEASTERN UNIVERSITY · PI Raymond G. Booth, Alexandros Makriyannis · 2022 to 2026
$1.3M
Genetic basis of binge eating and its motivational components in a reduced complexity crossR21DA038738 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BRYANT, CAMRON D · 2015 to 2016
$463k
Mapping G x E Interactions for Addiction Traits in a Reduced Complexity CrossR03DA038287 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BRYANT, CAMRON D · 2014 to 2015
$174k
NIDA NIH HHS R03 DA038287NIDA NIH HHS R21 DA038738NIDA NIH HHS T32 DA055553NIDA NIH HHS U01 DA050243NIDA NIH HHS U01 DA055299
6 · The paper itself

Abstract

Opioid use disorder is heritable, yet its genetic etiology is largely unknown. C57BL/6J and C57BL/6NJ mouse substrains exhibit phenotypic diversity in the context of limited genetic diversity which together can facilitate genetic discovery. Here, we found C57BL/6NJ mice were less sensitive to oxycodone (OXY)-induced locomotor activation versus C57BL/6J mice in a conditioned place preference paradigm. Narrow-sense heritability was estimated at 0.22-0.31, implicating suitability for genetic analysis. Quantitative trait locus (QTL) mapping in an F2 cross identified a chromosome 1 QTL explaining 7-12% of the variance in OXY locomotion and anxiety-like withdrawal in the elevated plus maze. A second QTL for EPM withdrawal behavior on chromosome 5 near

Identifiers

PMID38798314
PMCPMC11123399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.